Low dose oestrogen combined oral contraception and risk of pulmonary embolism, stroke, and myocardial infarction in five million French women: Cohort study

BMJ (Online)

Volumn 353, Issue , 2016, Pages

  Weill, Alain ^a   Dalichampt, Marie ^a   Raguideau, Fanny ^b   Ricordeau, Philippe ^a   Blotière, Pierre Olivier ^a   Rudant, Jérémie ^a   Alla, François ^a   Zureik, Mahmoud ^b  

^a French Public Health Insurance   (France)

^b Department of Epidemiology of Health Products   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DESOGESTREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ETHINYLESTRADIOL; ETHINYLESTRADIOL PLUS GESTODENE; ETHINYLESTRADIOL PLUS LEVONORGESTREL; GESTODENE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LEVONORGESTREL; NORETHISTERONE; NORGESTREL; ESTROGEN; ORAL CONTRACEPTIVE AGENT;

ADOLESCENT; ADULT; ARTICLE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CEREBROVASCULAR ACCIDENT; COHORT ANALYSIS; DISEASE ASSOCIATION; FEMALE; FRANCE; HEART INFARCTION; HOSPITAL DISCHARGE; HUMAN; LUNG EMBOLISM; OBSERVATIONAL STUDY; ORAL CONTRACEPTION; ORAL CONTRACEPTIVE USE; POPULATION RESEARCH; PRIORITY JOURNAL; REIMBURSEMENT; RISK ASSESSMENT; CHEMICALLY INDUCED; CONTRACEPTION; RISK FACTOR;

COHORT STUDIES; CONTRACEPTION; CONTRACEPTIVES, ORAL; CONTRACEPTIVES, ORAL, COMBINED; ESTROGENS; FEMALE; HUMANS; MYOCARDIAL INFARCTION; PULMONARY EMBOLISM; RISK FACTORS; STROKE;

EID: 84969785137     PISSN: 09598146     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.i2002     Document Type: Article

References (46)

1. Compiled by Earth Policy Institute from U.N. Population Division. World Contraceptive Use 2011, wall chart, February 2011. www.google.fr/url?sa=t&rct=j&q=&esrc=s&source=web&cd= 1&cad=rja&uact=8&ved=0CCMQFjAA&url=http%3A%2F%2F www.earth-policy.org%2Fdatacenter%2Fxls%2Fhighlights26-all. xls&ei=FZ0WVKPMOdTvaKXzgqgP&usg=AFQjCNF10wNQtG2aoPUgkK9YRymHRxb5cw&sig2=ZpqOHEY2CTVVkIA9WUrS4Q&bvm=bv.75097201,d.d2s
2. Vandenbroucke JP, Koster T, Briët E, Reitsma PH, Bertina RM, Rosendaal FR. Increased risk of venous thrombosis in oralcontraceptive users who are carriers of factor V Leiden mutation. Lancet 1994;344:1453-7. doi:10.1016/S0140-6736(94)90286-0.
3. Thorogood M, Mann J, Murphy M, Vessey M. Risk factors for fatal venous thromboembolism in young women: a case-control study. Int J Epidemiol 1992;21:48-52. doi:10.1093/ije/21.1.48.
4. World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study. Lancet 1995;346:1575-82. doi:10.1016/S0140-6736(95)91926-0.
5. Farmer RD, Lawrenson RA, Thompson CR, Kennedy JG, Hambleton IR. Population-based study of risk of venous thromboembolism associated with various oral contraceptives. Lancet 1997;349:83-8.doi:10.1016/S0140-6736(96)07496-X.
6. Parkin L, Skegg DCG, Wilson M, Herbison GP, Paul C. Oral contraceptives and fatal pulmonary embolism. Lancet 2000;355:2133-4. doi:10.1016/S0140-6736(00)02382-5.
7. van Hylckama Vlieg A, Helmerhorst FM, Vandenbroucke JP, Doggen CJ, Rosendaal FR. The venous thrombotic risk of oral contraceptives, effects of oestrogen dose and progestogen type: results of the MEGA case-control study. BMJ 2009;339:b2921. doi:10.1136/bmj. b2921.
8. Lidegaard ø, Løkkegaard E, Svendsen AL, Agger C. Hormonal contraception and risk of venous thromboembolism: national follow-up study. BMJ 2009;339:b2890. doi:10.1136/bmj.b2890.
9. Dinger J, Assmann A, Möhner S, Minh TD. Risk of venous thromboembolism and the use of dienogest- and drospirenonecontaining oral contraceptives: results from a German case-control study. J Fam Plann Reprod Health Care 2010;36:123-9.doi:10.1783/147118910791749416.
10. Parkin L, Sharples K, Hernandez RK, Jick SS. Risk of venous thromboembolism in users of oral contraceptives containing drospirenone or levonorgestrel: nested case-control study based on UK General Practice Research Database. BMJ 2011;342:d2139.doi:10.1136/bmj.d2139.
11. Jick SS, Hernandez RK. Risk of non-fatal venous thromboembolism in women using oral contraceptives containing drospirenone compared with women using oral contraceptives containing levonorgestrel: case-control study using United States claims data. BMJ 2011;342:d2151. doi:10.1136/bmj.d2151.
12. Lidegaard ø, Nielsen LH, Skovlund CW, Skjeldestad FE, Løkkegaard E. Risk of venous thromboembolism from use of oral contraceptives containing different progestogens and oestrogen doses: Danish cohort study, 2001-9. BMJ 2011;343:d6423. doi:10.1136/bmj.d6423.
13. Food and Drug Administration Office of Surveillance and Epidemiology. Combined hormonal contraceptives (CHCs) and the risk of cardiovascular disease endpoints (http://www.fda.gov/ downloads/Drugs/DrugSafety/UCM277384.pdf).
14. Gronich N, Lavi I, Rennert G. Higher risk of venous thrombosis associated with drospirenone-containing oral contraceptives: a population-based cohort study. CMAJ 2011;183:E1319-25.doi:10.1503/cmaj.110463.
15. Stegeman BH, de Bastos M, Rosendaal FR, et al. Different combined oral contraceptives and the risk of venous thrombosis: systematic review and network meta-analysis. BMJ 2013;347:f5298. doi:10.1136/ bmj.f5298.
16. Dunn N. Oral contraceptives and venous thromboembolism. BMJ 2009;339:b3164. doi:10.1136/bmj.b3164.
17. Bitzer J, Amy JJ, Beerthuizen R, et al. Statement on combined hormonal contraceptives containing third- or fourth-generation progestogens or cyproterone acetate, and the associated risk of thromboembolism. J Fam Plann Reprod Health Care 2013;39:156-9. doi:10.1136/ jfprhc-2013-100624.
18. Vinogradova Y, Coupland C, Hippisley-Cox J. Use of combined oral contraceptives and risk of venous thromboembolism: nested case-control studies using the QResearch and CPRD databases. BMJ 2015;350:h2135. doi:10.1136/bmj.h2135.
19. Poulter NR, Chang CL, Farley TM, Marmot MG, Meirik O. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Effect on stroke of different progestagens in low oestrogen dose oral contraceptives. Lancet 1999;354:301-2.doi:10.1016/S0140-6736(99)01013-2.
20. Heinemann LAJ, Lewis MA, Spitzer WO, Thorogood M, Guggenmoos-Holzmann I, Bruppacher R. Transnational Research Group on Oral Contraceptives and the Health of Young Women. Thromboembolic stroke in young women. A European case-control study on oral contraceptives. Contraception 1998;57:29-37. doi:10.1016/ S0010-7824(97)00204-7.
21. Lidegaard ø, Kreiner S. Contraceptives and cerebral thrombosis: a five-year national case-control study. Contraception 2002;65: 197-205. doi:10.1016/S0010-7824(01)00306-7.
22. Stampfer MJ, Willett WC, Colditz GA, Speizer FE, Hennekens CH. A prospective study of past use of oral contraceptive agents and risk of cardiovascular diseases. N Engl J Med 1988;319:1313-7. doi:10.1056/ NEJM198811173192004.
23. Lewis MA, Heinemann LAJ, Spitzer WO, MacRae KD, Bruppacher R. The use of oral contraceptives and the occurrence of acute myocardial infarction in young women. Results from the Transnational Study on Oral Contraceptives and the Health of Young Women. Contraception 1997;56:129-40. doi:10.1016/ S0010-7824(97)00118-2.
24. Poulter NR, Chang CL, Farley TMM, Kelaghan J, Meirik O, Marmot MG. WHO Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception. Acute myocardial infarction and combined oral contraceptives: results of an international multicentre case-control study. Lancet 1997;349:1202-9. doi:10.1016/ S0140-6736(97)02358-1.
25. Sidney S, Siscovick DS, Petitti DB, et al. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies. Circulation 1998;98:1058-63. doi:10.1161/01.CIR.98.11.1058.
26. Dunn N, Thorogood M, Faragher B, et al. Oral contraceptives and myocardial infarction: results of the MICA case-control study. BMJ 1999;318:1579-83. doi:10.1136/bmj.318.7198.1579.
27. Dunn NR, Arscott A, Thorogood M. The relationship between use of oral contraceptives and myocardial infarction in young women with fatal outcome, compared to those who survive: results from the MICA case-control study. Contraception 2001;63:65-9. doi:10.1016/ S0010-7824(01)00172-X.
28. Rosenberg L, Palmer JR, Rao RS, Shapiro S. Low-dose oral contraceptive use and the risk of myocardial infarction. Arch Intern Med 2001;161:1065-70. doi:10.1001/archinte.161.8.1065.
29. Tanis BC, van den Bosch MA, Kemmeren JM, et al. Oral contraceptives and the risk of myocardial infarction. N Engl J Med 2001;345:1787-93.doi:10.1056/NEJMoa003216.
30. Margolis KL, Adami HO, Luo J, Ye W, Weiderpass E. A prospective study of oral contraceptive use and risk of myocardial infarction among Swedish women. Fertil Steril 2007;88:310-6. doi:10.1016/j. fertnstert.2006.11.206.
31. Lidegaard ø, Løkkegaard E, Jensen A, Skovlund CW, Keiding N. Thrombotic stroke and myocardial infarction with hormonal contraception. N Engl J Med 2012;366:2257-66. doi:10.1056/ NEJMoa1111840.
32. Tuppin P, de Roquefeuil L, Weill A, Ricordeau P, Merlière Y. French national health insurance information system and the permanent beneficiaries sample. Rev Epidemiol Sante Publique 2010;58:286-90. doi:10.1016/j.respe.2010.04.005.
33. Moulis G, Lapeyre-Mestre M, Palmaro A, Pugnet G, Montastruc JL, Sailler L. French health insurance databases: What interest for medical research?Rev Med Interne 2015;36:411-7. doi:10.1016/j. revmed.2014.11.009.
34. Rey G, Jougla E, Fouillet A, Hémon D. Ecological association between a deprivation index and mortality in France over the period 1997 - 2001: variations with spatial scale, degree of urbanicity, age, gender and cause of death. BMC Public Health 2009;9:33. doi:10.1186/1471-2458-9-33.
35. Vessey M, Mant D, Smith A, Yeates D. Oral contraceptives and venous thromboembolism: findings in a large prospective study. Br Med J (Clin Res Ed) 1986;292:526. doi:10.1136/ bmj.292.6519.526.
36. Bloemenkamp KW, Rosendaal FR, Helmerhorst FM, Büller HR, Vandenbroucke JP. Enhancement by factor V Leiden mutation of risk of deep-vein thrombosis associated with oral contraceptives containing a third-generation progestagen. Lancet 1995;346:1593-6.doi:10.1016/S0140-6736(95)91929-5.
37. Gerstman BB, Piper JM, Tomita DK, Ferguson WJ, Stadel BV, Lundin FE. Oral contraceptive estrogen dose and the risk of deep venous thromboembolic disease. Am J Epidemiol 1991;133:32-7.
38. Haute Autorité de Santé. Correct use of medicinal products: Combined oral contraceptives: prefer 1st or 2nd generation pills. November 2012. www.hassante.fr/portail/upload/docs/application/ pdf/2012-12/contraceptis-oraux-3-g-fiche-bum.pdf
39. French Ministry of Labour. Employment and Health. Guide to the methodology of production of information on medical activity and billing in medicine, surgery, obstetrics and dentistry. Official Bulletin No. 2011/6 b. Special issue. June 2011. www.sante.gouv.fr/IMG/pdf/ sts-20110006-0001-p000.pdf
40. Casez P, Labarère J, Sevestre MA, et al. ICD-10 hospital discharge diagnosis codes were sensitive for identifying pulmonary embolism but not deep vein thrombosis. J Clin Epidemiol 2010;63:790-7.doi:10.1016/j.jclinepi.2009.09.002.
41. Aboa-Eboulé C, Mengue D, Benzenine E, et al. How accurate is the reporting of stroke in hospital discharge data? A pilot validation study using a population-based stroke registry as control. J Neurol 2013;260:605-13. doi:10.1007/s00415-012-6686-0.
42. Suissa S, Spitzer WO, Rainville B, Cusson J, Lewis M, Heinemann L. Recurrent use of newer oral contraceptives and the risk of venous thromboembolism. Hum Reprod 2000;15:817-21. doi:10.1093/ humrep/15.4.817.
43. Zhang G, Xu X, Su W, Xu Q. Smoking and risk of venous thromboembolism: a systematic review. Southeast Asian J Trop Med Public Health 2014;45:736-45.
44. Dinger JC, Heinemann LA, Kühl-Habich D. The safety of a drospirenone-containing oral contraceptive: final results from the European Active Surveillance Study on oral contraceptives based on 142,475 women-years of observation. Contraception 2007;75:344-54. doi:10.1016/j.contraception.2006.12.019.
45. Bajos N, Bohet A, Le Guen M, Moreau C. Fecond Survey Team. Contraception in France: new context, new practices?Popul Soc (Paris) 2012;492. www.ined.fr/fichier/t-publication/1606/publi-pdf2- pesa492.pdf.
46. Tricotel A, Collin C, Zureik M. Impact of the sharp changes in the use of contraception in 2013 on the risk of pulmonary embolism in France. J Thromb Haemost 2015;13:1576-80. doi:10.1111/jth.13053.